SRR25617901
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- INTERFERON_GAMMA_RESPONSE+0.480
- PROTEIN_SECRETION+0.360
- IL6_JAK_STAT3_SIGNALING+0.250
- INFLAMMATORY_RESPONSE+0.230
- PI3K_AKT_MTOR_SIGNALING+0.150
- HEME_METABOLISM+0.140
- OXIDATIVE_PHOSPHORYLATION+0.140
- TNFA_SIGNALING_VIA_NFKB+0.140
- DNA_REPAIR+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- ANGIOGENESIS-0.450
- WNT_BETA_CATENIN_SIGNALING-0.450
- MYC_TARGETS_V2-0.360
- HEDGEHOG_SIGNALING-0.330
- MYOGENESIS-0.330
- NOTCH_SIGNALING-0.300
- APICAL_JUNCTION-0.260
- COAGULATION-0.250
- UV_RESPONSE_DN-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d7472c45-93c1-4237-82ac-c17e863b9a58 | — | — | 0.811 |
| 2 | aMVAC.P_006_TURBT_S224 | — | — | 0.792 |
| 3 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.777 |
| 4 | SRR33532827 | — | D | 0.776 |
| 5 | SRR12202424 | — | — | 0.764 |
| 6 | SRR2016949 | — | — | 0.746 |
| 7 | TCGA-EW-A1J5-01A-11R-A13Q-07 | — | B | 0.743 |
| 8 | TCGA-EW-A1J6-01A-11R-A13Q-07 | — | B | 0.743 |
| 9 | 17-071pB9_FFPE | — | — | 0.742 |
| 10 | s0122212 | — | — | 0.742 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |